Signal transduction targets in prostate cancer

Current Signal Transduction Therapy

Volumn 3, Issue 2, 2008, Pages 112-128

  Koul, Hari K ^a,b   Khandrika, Lakshmipathi ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

ERK5 Activation; LNCaP cells; MAP kinase; Proliferation; Protein Signaling

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ANDROGEN RECEPTOR; DISHEVELLED 1; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEINASE ACTIVATED RECEPTOR 4; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR ELK 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; WNT1 PROTEIN;

APOPTOSIS; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INACTIVATION; GENE INTERACTION; GENE LOSS; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSLOCATION; GROWTH INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 54949105047     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436208784223143     Document Type: Review

References (262)

1. Reynolds AR, Kyprianou N. Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol 2006; 147 (Suppl 2): S144-52.
2. Cronauer MV, Schulz WA, Burchardt T, et al. The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling. Int J Oncol 2003; 23: 1095-102.
3. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-7.
4. Chan TO, Rittenhouse SE, Tsichlis PN. Akt/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem 1999; 68: 965-1014.
5. Graff JR. Emerging targets in the AKT pathway for the treatment of androgen independent prostatic adenocarcinoma. Expert Opin Ther Target 2002; 6: 103-13.
6. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ Akt pathway. Proc Natl Acad Sci USA 1999; 96: 4240-5.
7. Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and Mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 2004; 64: 6190-9.
8. Vander Griend DJ, Kocherginsky M, Hickson JA, Stadler WM, Lin A, Rinker-Schaeffer CW. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinase JNKK1/MKK4 and MKK7. Cancer Res 2005; 65: 10984-91.
9. Ray G, Dhar G, Van Veldhuizen PJ, et al. Modulation of cell-cycle regulatory signaling network by 2-Methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways. Biochemistry 2006; 4: 3711-21.
10. Magi-Galluzzi C, Montironi R, Cangi MG, Wishnow K, Loda M. Mitogen-activated protein kinases and apoptosis in PIN. Virchows Arch 1998; 432: 407-13.
11. Torii S, Kusakabe M, Yamamoto T, Maekawa M, Nishida E. Sef is a spatial regulator for Ras/MAP kinase signaling. Dev Cell 2004; 7: 33-44.
12. Royuela M, Arenas MI, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R. Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum Pathol 2002; 33: 299-306.
13. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999; 59: 279-84.
14. Suthiphongchai T, Promyart P, Virochrut S, Tohtong R, Wilairat P. Involvement of ERK1/2 in invasiveness and metastatic development of rat prostatic adenocarcinoma. Oncol Res 2003; 13: 253-9.
15. van Bokhoven A, Caires A, Maria MD, et al. Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines. Prostate 2003; 57: 226-44.
16. Pang ST, Weng WH, Flores-Morales A, et al. Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer. Prostate 2006; 66: 157-72.
17. Koochekpour S, Sartor O, Hiraiwa M, et al. Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells. Asian J Androl 2005; 7: 147-58.
18. Meinbach DS, Lokeshwar BL. Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence? Urol Oncol 2006; 24: 294-306.
19. Pandini G, Mineo H, Frasca F, et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 2005; 65: 1849-57.
20. Guo C, Luttrell LM, Price DT. Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol 2000; 163: 1027-32.
21. Jani AB. Management strategies for locally advanced prostate cancer. Drugs Aging 2006; 23: 119-29.
22. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488-90.
23. Baldi E, Bonaccorsi L, Forti G. Androgen receptor: good guy or bad guy in prostate cancer invasion? Endocrinology 2003; 144: 1653-5.
24. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
25. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene 1999; 18: 6322-9.
26. Bell WC, Myers RB, Hosein TO, Oelschlager DK, Grizzle WE. The response of extracellular signal-regulated kinase (ERK) to androgen-induced proliferation in the androgen-sensitive prostate cancer cell line, LNCaP. Biotech Histochem 2003; 78: 11-16.
27. Unni E, Sun S, Nan B, et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004; 64: 7156-68.
28. Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004; 91: 491-503.
29. Hakariya T, Shida Y, Sakai H, Kanetake H, Igawa T. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K Akt pathway as LNCaP prostate cancer cells. Biochem Biophys Res Comm 2006; 342: 92-100.
30. Ueda T, Mawji NH, Bruchovsky N, Sadar MD. Ligand independent activation of the androgen receptor by IL-6 arid the role of the coactivator SRC-1 in prostate cancer cells. J Biol Chem 2002; 277: 38087-94.
31. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20.
32. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to anti-androgen therapy. Nat Med 2004; 10: 33-39.
33. Yang L, Wang L, Lin HK, et al. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 2003; 305: 462-9.
34. Steiner H, Godoy-Tundidor S, Rogatsch H, et al. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 2003; 162: 655-63.
35. Koul S, Huang M, Chaturvedi L, Meacham RB, Koul HK. p42/p44 Mitogen-activated protein kinase signal transduction pathway regulates interleukin-6 expression in PC3 cells, a line of hormone-refractory prostate cancer cells. Ann NY Acad Sci 2004; 1030: 253-7.
36. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54: 5474-8.
37. Lorenzo GD, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to andragon-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-44.
38. Zi X, Singh RP, Agarwal R. Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. Carcinogenesis 2000; 21: 2225-35.
39. Murillo H, Schmidt LJ, Tindall DJ. Tyrphostin AG825 triggers p38 Mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2. Cancer Res 2001; 61: 7408-12.
40. Stewart LV, Lyles B, Lin MF, Weigel NL. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol 2005; 97: 37-46.
41. Unlu A, Leake RE. The effect of EGFR-related tyrosine kinase activity inhibition on the growth and invasion mechanisms of prostate carcinoma cell lines. Int J Biol Markers 2003; 18: 139-46.
42. Raj GV, Barki-Harrington L, Kue PF, Daaka Y. Guanosine phosphate binding protein coupled receptors in prostate cancer: a review. J Urol 2002; 167: 1458-63.
43. Kue, PF, Taub JS, Barrington LB, Polakiewicz RD, Ullrich A, Daaka V. Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells. Int J Cancer 2002; 102: 572-9.
44. Xiao D, Qu X, Weber HC. Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell Signal 2003; 15: 945-53.
45. Kue PF, Daaka Y. Essential role for G proteins in prostate cancer cell growth and signaling. J Urol 2000; 164: 2162-7.
46. O'Flaherty JT, Rogers LC, Chadwell BA, et al. (S)-Hydroxy-6,8,11,14-E,Z,Z,Z-eicosatetraenoate stimulates PC3 cell signaling and growth by a receptor-dependent mechanism. Cancer Res 2002; 62: 6817-29.
47. Spiegel S, Milstien S. Critical role of acylglycerol kinase in epidermal growth factor-induced mitogenesis of prostate cancer cells. Biochem Soc Trans 2005; 33: 1362-5.
48. Stangelberger A, Schally AV, Varga JL, et al. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signaling. Eur J Cancer 2005; 41: 2735-44.
49. Jiang C, Ganther H, Lu J. Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog 2000; 29: 236-50.
50. Hu H, Jiang C, Li G, Lü J. PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis 2005; 26: 1374-81.
51. Deocampo ND, Huang H, Tindall DJ. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol 2003; 28: 145-53.
52. Ling MT, Wang X, Ouyang XS, et al. Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. Oncogene 2002; 21: 8498-505.
53. Zhou J, Scholes J, Hsieh JT. Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem 2003; 278: 6936-41.
54. Wu O, Foreman TL, Gregory CW, et al. Protein kinase c epsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res 2002; 62: 2423-9.
55. Kiefer JA, Farach-Carson MC. Type I collagen-mediated proliferation of PC3 prostate carcinoma cell line: implications for enhanced growth in the bone microenvironment. Matrix Biol 2001; 20: 429-37.
56. Liu L, Xie Y, Lou L. PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 Activation. Eur J Cell Biol 2006; 85: 367-74.
57. Lin CL, Wang FS, Kuo YR, et al. Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int 2006; 69: 1593-600.
58. Shack S, Gorospe M, Fawcett TW, Hudgins WR, Holbrook NJ. Activation of the cholesterol pathway and Ras maturation in response to stress. Oncogene 1999; 18: 6021-8.
59. Danesi R, Nardini D, Basolo F, Del Tacca M, Samid D, Myers CE. Pheny-lacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. Mol Pharmacol 1996; 49: 972-9.
60. Burger M, Denzinger S, Hammerschmied C, et al. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Eur Urol 2006; 50: 1102-9.
61. Ravi RK, McMahon M, Yangang Z, et al. Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. J Cell Biochem 1999; 72: 458-69.
62. Fu Z, Smith PC, Zhang L, et al. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003; 95: 878-89.
63. Fu Z, Kitagawa Y, Shen R, et al. Metastasis Suppressor Gene Raf Kinase Inhibitor Protein (RKIP) Is a Novel Prognostic Masker in Prostate Cancer. Prostate 2006; 66: 248-56.
64. Sheta EA, Harding MA, Conaway MR, Theodorescu D. Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor. J Natl Cancer Inst 2000; 92: 1065-73.
65. Hsi LC, Wilson LC, Eling TE. Opposing effects of 15-lipoxygenase-1 and-2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. J Biol Chem 2002; 277: 40549-56.
66. Franco OE, Onishi T, Yamakawa K, et al. Mitogen-activated protein kinase pathway is involved in androgen-independent PSA gene expression in LNCaP cells. Prostate 2003; 56: 319-25.
67. Zhang J, Liu L, Pfeifer GP. Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene. Oncogene 2003; 22: 6704-16.
68. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 2002; 277: 50081-6.
69. Udayakumar TS, Stratton MS, Nagle RB, Bowden GT. Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3. Neoplasia 2002; 4: 60-7.
70. Yacoub A, Park JS, Qiao L, Dent P, Hagan MP. MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion. Int J Radiat Biol 2001; 77: 1067-78.
71. Onishi T, Yamakawa K, Franco OE, et al. Mitogen-activated protein kinase pathway is involved in alpha6 integrin gene expression in androgen-independent prostate cancer cells: role of proximal Sp1 consensus sequence. Biochim Biophys Acta 2001; 1538: 218-27.
72. Cheung HW, Ling MT, Tsao SW, Wong YC, Wang X. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 2004; 25: 881-7.
73. Lin JC, Chang SY, Hsieh DS, Lee CF, Yu DS. Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells. J Urol 2005; 174: 2022-6.
74. Lin HY, Shin A, Davis FB, et al. Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol 2002; 168: 748-55.
75. Xiao D, Singh SV. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res 2002; 62: 3615-9.
76. Xu C, Shen G, Yuan A, et al. ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells. Carcinogenesis 2006; 27: 437-45.
77. Tuohimaa P, Lyakhovich A, Aksenov N, et al. Vitamin D and prostate cancer. J Steroid Biochem Mol Biol 2001; 76: 125-34.
78. Gschwend JE, Fair WR, Powell CT. Bryostatin 1 induces prolonged activation of extracellular regulated protein kinases in and apoptosis of LNCaP human prostate cancer cells overexpressing protein kinase c alpha. Mol Pharmacol 2000; 57: 1224-34.
79. Kumar AP, Garcia GE, Slaga TJ 2-Methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog 2001; 31: 111-24.
80. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate 2001; 46: 98-107.
81. McKinstry R, Qiao L, Yacoub A, et al. Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. Cancer Biol Ther 2002; 1: 243-53.
82. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003; 159: 439-52.
83. Zelivianski S, Spellman M, Kellerman M, et al. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 2003; 107: 478-85.
84. Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S, Konishi N. Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells. Mol Carcinog 2002; 35: 127-37.
85. Shimada K, Nakamura M, Ishida E, Kishi M, Konishi N. Requirement of c-jun for testosterone-induced sensitization to N-(4-hydroxyphenyl)retinamide-induced apoptosis. Mol Carcinog 2003; 36: 115-22.
86. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC. Up-regulation of CXCR4 expression in PC-3 cells by Stromal- Derived Factor-1α (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-κB activation. Cancer Res 2005; 65: 9891-8.
87. Small GW, Shi YY, Edmund NA, Somasundarum S, Moore DT, Orlowski RZ. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 2004; 66: 1478-90.
88. Uzgare AR, Kaplan PJ, Greenberg NM. Differential expression and/or activation of P38MAPK, ERK1/2, and jnk during the initiation and progression of prostate cancer. Prostate 2003; 55: 128-39.
89. Basu A, Haldar S. Identification of a novel Bcl-xL, phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett 2003; 538: 41-7.
90. Tawadros T, Martin D, Abderrahmani A, Leisinger HJ, Waeber O, Haefliger JA. IB1/JIP-1 controls JNK activation and increased during prostatic LNCaP cells neuroendocrine differentiation. Cell Signal 2005; 17: 929-39.
91. Ghosh J. Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem Biophys Res Commun 2003; 307: 342-9.
92. Wartenberg M, Ling FC, Schallenberg M, et al. Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. J Biol Chem 2001; 276: 17420-8.
93. Engedal N, Korkmaz CG, Saatcioglu F. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene 2002; 21: 1017-27.
94. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004; 15: 177-82.
95. Yoon HS, Kim HA. Prolongation of c-Jun N-terminal kinase is associated with cell death induced by tumor necrosis factor alpha in human chondrocytes. J Korean Med Sci 2004; 19: 567-3.
96. Sah NK, Munshi A, Kurland JF, McDonnell TJ, Su B, Meyn RE. Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem 2003; 278: 20593-602.
97. Ranganathan P, Rangnekar VM. Regulation of Cancer Cell Survival by Par-4. Ann NY Acad Sci 2005; 1059: 76-85.
98. Garcia-Cao I, Lafuente MJ, Criado LM, Diaz-Meco MT, Serrano M, Moscat J. Genetic inactivation of Par4 results in hyperactivation of NF-kappaB and impairmentof JNK and p38. EMBO Rep 2003; 4: 307-12.
99. Bowen C, Birrer M, Gelmann EP. Retinoblastoma protein-mediated apoptosis after gamma-irradiation. J Biol Chem 2002; 277: 44969-79.
100. Costa-Pereira AP, McKenna SL, Cotter TG. Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis. Br J Cancer 2000; 82: 1827-34.
101. Moore TM, Garg R, Johnson C, Coptcoat MJ, Ridley AJ, Morris JD. PSK, a novel STE20-like kinase derived from prostatic carcinoma that activates the c-Jun N-terminal kinase mitogen-activated protein kinase pathway and regulates actin cytoskeletal organization. Biol Chem 2000; 275: 4311-22.
102. Han SY, Kim SH, Heasley LE. Differential gene regulation by specific gain-of-function JNK1 proteins expressed in Swiss 3T3 fibroblasts. J Biol Chem 2002; 277: 47167-74.
103. Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondaty site. J Urol 2003; 169: 1122-33.
104. Chen YR, Han J, Kori K, Kong AN, Tan TH. Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase. J Biol Chem 2002; 277: 39334-42.
105. Cho SD, Li G, Hu H, et al. Involvement of c-Jun N-terminal kinase in G2/M arrest and caspase-mediated apoptosis induced by sulforaphane in DU145 prostate cancer cells. Nutr Cancer 2005; 52: 213-24.
106. Srikanth S, Franklin CC, Duke RC, Kraft RS. Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol Cell Biochem 1999; 199: 169-78.
107. Gioeli D, Black BE, Gordon V, et al. Stress kinase signaling regulates androgen receptor phosphorylation, transcription and localization. Mol Endocrinol 2006; 20: 503-15.
108. Curtin JF, Cotter TG. JNK regulates HIPK3 expression and promotes resistance to fas-mediated apoptosis in DU145 prostate carcinoma cells. J biol Chem 2004; 279: 17090-100.
109. Shimada K, Nakamura M, Ishida E, Konishi N. Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer. Histol Histopathol 2006; 21: 415-22.
110. Curtin JF, Cotter TG. Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosia. Br J Cancer 2002; 87: 1188-94.
111. Potapova O, Anisimov SV, Gorospe M, et al. Targets of c-Jun NH(2)-terminal kinase 2-mediated tumor growth regulation revealed by serial analysis of gene expression. Cancer Res 2002; 62: 3257-63.
112. Eandi JA, Yang JC, Evans CP. Signal transduction-mediated regulation of urokinase gene expression in human prostate cancer. Biochem Biophys Res Commun 2001; 288: 521-27.
113. Grosch S, Tegeder I, Schilling K, Maier TJ, Niedreberger H, Geisslinger G. Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. FASEB J 2003; 17: 1316-8.
114. Shabsigh A, Ghafur MA, de la Taille A, et al. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 2001; 81: 437-44.
115. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle 2003; 2: 199-201.
116. Kennedy NJ, Sluss HK, Jones SN, Bar-Sagi B, Flavell HA, Davis RJ. Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev 2003; 17: 629-37.
117. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-52.
118. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100: 2432-7.
119. Zu K, Hawthorn L, Ip C. Up-regulation of c-Jun-NH2-kinase pathway contributes to the induction of mitochondria-mediated apoptosis by α-tocopheryl succinate in human prostate cancer cells. Mol Cancer Ther 2005; 4: 43-50.
120. Shimada K, Matsuyoshi S, Nakamura M, Ishida H, Kishi M, Konishi N. Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced Apoptosis. Carcinogenesis 2004; 25: 1089-97.
121. Yang YM, Bost F, Charbono W, et al. C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 2003; 9: 391-401.
122. Gjerset R, Haghighi A, Lebedeva S, Mercola D. Gene therapy approaches to sensitization of human prostate carcinoma to cisplatin by adenoviral expression of p53 and by antisense jun kinase oligonucleotide methods. Methods Mol Biol 2001; 175: 495-520.
123. Mehta PB, Robson CN, Neal DE, Leung HY. Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells. Oncogene 2001; 20: 5359-65.
124. Kim J, Adam RM, Freeman MR. Activation of the ERK mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res 2002; 62: 1549-54.
125. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 1997; 15: 2705-16.
126. Stein B, Brady H, Yang MX, Young DB, Barbosa MS. Cloning and characterization of MEK-6, a novel member of the mitogen-activated protein kinase kinase cascade. J Biol Chem 1996; 271: 11427-33.
127. Ricote M, Royuela M, Garcia-Tunon I, Bethencourt FR, Paniagua K, Fraile B. Pro-apoptotic tumor necrosis factor-alpha transduction pathway in normal prostate, benign prostatic hyperplasia and prostatic carcinoma. J Urol 2003; 170: 787-90.
128. Ricote M, Garcia-Tunon I, Bethencourt FR, Fraile B, Paniagua K, Royuela M. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004; 100: 1388-96.
129. Raingeaud J, Gupta S, Rogers JS, et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995; 270: 7420-6.
130. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 2003; 278: 33753-62.
131. Zoumpourlis V, Papassava P, Linardopoulos S, Gillespie D, Balmain A, Pintzas A. High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins-correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene 2000; 19: 4011-21.
132. Recio JA, Noonan FP, Takayama H, et al. Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis. Cancer Res 2002; 62: 6724-30.
133. Huynh H. Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol 2002; 20: 1297-303.
134. Xiao D, Qu X, Weber HC. GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells. Regul Pept 2002; 109: 141-8.
135. Ricote M, Garcia-Tunon I, Bethencourt F, et al. The p38 transduction pathway in prostatic neoplasla. J Pathol 2006; 208: 401-7.
136. Ricote M, Garcia-Tunon I, Fraile B, et al. p38 MAPK protects against TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells. Apoptosis 2006; 11: 1969-75.
137. Chen L, He HY, Li HM, et al. ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett 2004; 215: 239-47.
138. Shimada K, Nakamura M, Ishida E, Kishi M, Konishi N. Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 2003; 24: 1067-75.
139. Permpongkosol S, Wang JD, Takahara S, et al. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer 2002; 98: 167-72.
140. Gao N, Jiang BH, Leonard SS, et al. p38 Signaling-mediated hypoxia-inducible factor 1 alpha and vascular endotheial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. J Biol Chem 2002; 277: 45041-8.
141. Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 2001; 7: 1773-81.
142. Edlund S, Landstrom M, Heldin CH, Aspenstrom P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 2002; 13: 902-14.
143. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63: 1684-95.
144. Skjoth IH, Issinger OG. Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int J Oncol 2006; 28: 217-29.
145. Price DT, Rocca GD, Guo C, Ballo MS, Schwinn DA, Luttrell LM. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 1999; 162: 1537-42.
146. Huynh H, Nguyen TT, Chan E, Tran E. Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-alpha)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation. Int J Oncol 2003; 23: 821-9.
147. Wetterau LA, Francis MJ, Ma L, Cohen P. Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. J Clin Endocrinol Metab 2003; 88: 3354-9.
148. Udayakumar TS, Bair EL, Nagle RB, Bowden GT. Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, proliferation, and PSA expression. Mol Carcinog 2003; 38: 70-7.
149. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6- and cyclic AMP-mediated signaling potentates Neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001; 21: 8471-82.
150. Xie Y, Gibbs TC, Mukhin YV, Meier KE. Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J Biol Chem 2002; 277: 32516-26.
151. Barki-Harrington L, Daaka Y. Bradykinin induced mitogenesis of androgen independent prostate cancer cells. J Urol 2001; 165: 2121-5.
152. Lee YF, Lin WJ, Huang J, et al. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res 2002; 62: 6039-44.
153. Tessier DM, Matsumura F. Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides. Toxicol Sci 2001; 60: 38-43.
154. Segawa N, Nakamura M, Nakamura Y, Mori I, Katsuoka Y, Kakudo K. Phosphorylation of mitogen-activated protein kinase is inhibited by calcitonin in DU145 prostate cancer cells. Cancer Res 2001; 61: 6060-3.
155. Tyagi A, Agarwal R, Agarwal C. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene 2003; 22: 1302-16.
156. Jiang C, Wang Z, Ganther H, Lu J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 2002; 1: 1059-66.
157. Sharma Y, Agarwal C, Singh AK, Agarwal R. Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells. Mol Carcinog 2001; 30: 224-36.
158. Wang S, DeGroff VL, Clinton SK. Tomato and soy polyphenols reduce insulin-like growth factor-1-stimulated rat prostate cancer cell proliferation and apoptotic resistance in vitro via inhibition of intracellular signaling pathways involving tyrosine kinase. J Nut 2003; 133: 2367-76.
159. Park JI, Lee MG, Cho K, et al. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 2003; 22: 4314-32.
160. Bu S, Blaukat A, Fu X, Heldin NE, Landstrom M. Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett 2002; 531: 141-51.
161. Drew L, Fine RL, Do TN, Douglas GP, Petrylak DP. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells. Clin Cancer Res 2002; 8: 3922-32.
162. Uzzo RG, Leavis P, Hatch W, et al. Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents. Clin Cancer Res 2002; 8: 3579-83.
163. Lu S, Hoestje SM, Choo EM, Epner DE. Methionine restriction induces apoptosis of prostate cancer cells via the c-Jun N-terminal kinase-mediated signaling pathway. Cancer Lett 2002; 179: 51-8.
164. Maeda H, Hori S, Nishitoh H, et al. Tumor growth inhibition by arsenic trioxide (As203) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001; 61: 5432-40.
165. Chen YR, Zhou G, Tan TH. c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide. Mol Pharmacol 1999; 56: 1271-9.
166. Mukhopadhyay A, Bueso-Ramos C, Chattrjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001; 20: 7597-609.
167. Lee TJ, Sartor O, Luftig RB, Koochekpour S. Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells. Mol Cancer 2004; 3: 31.
168. Yeh AH, Jeffery PL, Duncan RP, Herington AC, Chopin LK. Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clin Cancer Res 2005; 11: 8295-303.
169. Wang X, Clubbs EA, Bomser JA. Genistein modulates prostate epithelial cell proliferation via estrogen- and extracellular signal-regulated kinase-dependent pathways. J Nutr Biochem 2006; 17: 204-10.
170. Vayalil PK, Mittal A, Katiyar SK. Proanthocyanidins from grape seeds inhibit expression of matrix metalloproteinases in human prostate carcinoma cells, which is associated with the inhibition of activation of MAPK and NFκB. Carcinogenesis 2004; 25: 987-95.
171. Cho SD, Ahn NS, Jung JW, et al. Critical role of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate cancer cells. Eur J Cancer Prev 2006; 15: 57-63.
172. Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate Cancer Cell-Adipocyte Interaction: Leptin mediates androgen-independent prostate cancer cell proliferation through C-jun NH2-terminal kinase. J Biol Chem 2003; 278: 42660-7.
173. Culig Z, Hobisch A, Cronauer MV, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996 Jun;28(6):392-405.
174. Mehta PB, Jenkins BL, McCarthy L, et al. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene 2003; 22: 1381-9.
175. Esparís-Ogando A, Díaz-Rodríguez E, Montero JC, Yuste L, Crespo P, Pandiella A. ERK5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 2002; 22: 270-85.
176. Robinson D, He F, Pretlowt T, Kung HJ. A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA 1996; 93: 5958-62.
177. Mody N, Campbell DG, Morrice N, Peggie M, Cohen P. An analysis of the phosphorylation and activation of extracellular-signal-regulated protein kinase 5 (ERK5) by mitogen-activated protein kinase kinase 5 (MKK5) in vitro. Biochem J 2003; 372: 567-75.
178. Wood M, Fudge K, Mohler JL, et al. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997; 15: 246-58.
179. Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer 2001; 93: 507-15.
180. Weldon CB, Scandurro AB, Rolfe KW, et al. Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery 2002; 132: 293-301.
181. Buschbeck M, Hofbauer S, Croce LD, Keri G, Ullrich A. Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival. EMBO Rep 2005; 6: 63-9.
182. Hayashi M, Fearns C, Eliceiri B, Yang Y, Lee JD. Big mitogen-activated protein kinase 1/Extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Cancer Res 2005; 65: 7699-706.
183. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD. Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 1998; 395: 713-6.
184. Marinissen MJ, Chiariello M, Pallante M, Gutkind JS. A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. Mol Cell Biol 1999; 19: 4289-301.
185. Chao TH, Hayashi M, Tapping RI, Kato Y, Lee JD. MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway. J Biol Chem 1999; 274: 36035-8.
186. Sun W, Kesavan K, Schaefer BC, et al. MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-HMK1/ERK5 pathway. J Biol Cbem 2001; 276: 5093-100.
187. Seyfried J, Wang X, Kharebava G, Tournier C. A novel mitogen-activated protein kinase docking site in the N terminus of MEK5 alpha organizes the components of the extracellular signal-regulated kinase 5 signaling pathway. Mol Cell Biol 2005; 25: 9820-8.
188. Sun W, Wei X, Kesavan K, et al. MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src. Mol Cell Biol 2003, 23: 2298-308.
189. Nakaoka Y, Nishida K, Fujio Y, et al. Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/ docking protein Gab 1 with tyrosine phosphatase SHP2 in cardiomyocytes. Circ Res 2003; 93: 221-9.
190. Dodge-Kafka KL, Soughayer J, Pare GC, et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 2005; 437: 574-8.
191. Rodriguez-Viciana P, Warne PH, Khwaja A, et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Res. Cell 1997; 89: 457-67.
192. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10: 262-7.
193. Scapoli L, Ramos-Nino ME, Martinelli M, Mossman BT. Src-dependent ERK5 and Src/EGFR-dependent ERK1/2 activation is required for cell proliferation by asbestos. Oncogene 2004; 23: 805-13.
194. Barros JC, Marshall CJ. Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. J Cell Sci 2005; 118: 1663-71.
195. Kondoh K, Terasawa K, Morimoto H, Nishida E. Regulation of nuclear translocation of Extracellular signal-regulated kinase 5 by active nuclear import and export mechanisms. Mol Cell Biol 2006; 26: 1679-90.
196. Yan C, Luo H, Lee JD, Abe JI, Berk BC. Molecular cloning of mouse ERK5/ BMK1 splice variants and characterization of ERK5 functional domains. J Biol Chem 2001; 276: 10870-8.
197. Kayahara M, Wang X, Tournier C. Selective regulation of c-jun gene expression by mitogen-activated protein kinases via the 12-o-tetradecanoylphorbol-13-acetate- responsive element and myocyte enhancer factor 2 binding sites. Mol Cell Biol 2005; 25: 3784-92.
198. Pearson G, English JM, White MA, Cobb MH. ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem 2001; 276: 7927-31.
199. Pi X, Yan C, Berk BC. Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis. Circ Res 2004; 94: 362-9.
200. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in ptenC/K mice. Cancer Res 2000; 60: 3605-11.
201. Lu S, Ren C, Liu Y, Epner DE. PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells. Int J Oncol 2006; 28: 245-51.
202. Chung JH, Ginn-Pease ME, Eng C. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res 2005; 65: 4108-16.
203. Liu JL, Sheng A, Hortobagyi ZK, Mao Z, Gallick GE, Yung WK. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 2005; 25: 6211-24.
204. Irvine RF. Nuclear lipid signaling. Nat Rev Mol Cell Biol 2003; 4: 349-60.
205. Van de Sande T, Roskams T, Lerut E, et al. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB. J Pathol 2005; 206: 214-9.
206. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
207. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al. Suppression of c-Myc-induced apoptosis by Ras signaling through PI (3)K and PKB. Nature 1997; 385: 544-8.
208. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-95.
209. Chinni SR, Sivalogan S, Dong Z. et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006; 66: 32-48.
210. Bonaccorsi L, Carloni V, Muratori M, et al. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 2004; 112: 78-86.
211. Persad S, Attwell S, Gray V, et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 2000; 97: 3207-12.
212. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29: 233-42.
213. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-82.
214. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
215. Hughes-Fulford M, Li CF, Boonyaratanakomkit, Sayyah S. Arachidonic acid activates Phosphatidylinositol 3-Kinase signaling and induces gene expression in prostate cancer. Cancer Res 2006; 66: 1427-33.
216. Le Page C, Koumakpayi IH, Lessard L, Saad F, Mes-Masson AM. Independent role of PhosphoInositol-3-Kinase (PI3K) and Casein Kinase II (CK-2) in EGFR and Her-2 mediated constitutive NF-kappaB activation in prostate cancer cells. Prostate 2005; 65: 306-15.
217. Lin HK, Yeh S, Kang HY, Chang C. Akd suppress androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-5.
218. Yamaguchi H, Wang HG. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 2001; 20: 7779-86.
219. Goswami A, Burikhanov R, de Thonel A, et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 3005; 20: 33-44.
220. Kim JH, Xu C, Keum YS, Reddy B, Conney A, Kong AN. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 2006; 27: 475-82.
221. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt dependent prostate intraepithelial neoplasia through regulation of apoptotic and HKF-1-dependent pathways. Nat Med 2004; 10: 594-601.
222. Garikapaty VPS, Ashok BT, Tadi K, Mittelman A, Tiwari RK 3,3′-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochem Biophys Res Commun 2006; 340: 718-25.
223. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005; 24: 7465-74.
224. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P. Therapeutic potential of phosphoinositide 3-kinase inbibitors. Chem Biol 2003; 10: 207-13.
225. Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans 2004; 32: 393-6.
226. Cerezo A, Martinez AC, Lanzarot D, Fischer S, Franke TF, Rebollo A. Role of Akt and c-Jun N-terminal kinase 2 in apoptosis induced by interleukin-4 deprivation. Mol Biol Cell 1998; 9: 3107-18.
227. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 2001; 21: 893-901.
228. Barthwal MK, Sathyanarayana P, Kundu CN, et al. Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival. J Biol Chem 2003; 278: 3897-902.
229. Kwon T, Kwon DY, Chun J, Kim JH, King SS. Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 2000; 275: 423-8.
230. Zhang TJ, Hoffman BG, Ruiz de Algara T, Helgason CD. SAGE reveals expression of Wnt signalling pathway members during mouse prostate development Gene Expr Patterns 2006; 6: 310-24.
231. Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol Oncol 2005; 23: 402-6.
232. Chen G, Shukeir N, Potti A, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 2004; 101: 1345-56.
233. Mizutani K, Miyamoto S, Nagahata T, Konishi N, Emi M, Onda M. Upregulation and overexpression of DVL1, the human counterpart of the Drosophila dishevelled gene, in prostate cancer. Tumori 2005; 91: 546-51.
234. Behrens J, Jerchow BA, Wurtele M, et al. Functional interaction of an axin homolog, conductin, with β-catenin, APC and GSK3β. Science 1998; 280: 596-9.
235. Nakamura T, Hamada F, Ishidate T, et al. Axin, an inhibitor of the Wnt signalling pathway, interacts with β-catenin, GSK-3β and APC and reduces the β-catenin level. Genes Cells 1998; 3: 395-403.
236. Kitagawa M, Hatakeyama S, Shirane M, et al. An F-box protein. FWD1, mediates ubiquitin-dependent proteolysis of β-catenin. EMBO J 1999; 18: 2401-10.
237. Verras M, Sun Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett 2006; 237: 22-32.
238. Roose J, Huls G, van Beest M, et al. Synergy between tumor suppressor APC and the β-catenin-Tcf4 target Tcf1. Science 1999; 285: 1923-6.
239. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335-45.
240. Voeller HJ, Truica CI, Gelmann EP. β-Catenin mutations in human prostate cancer. Cancer Res 1998; 58: 2520-3.
241. Truica CI, Byers S, Gelmann EP. β-Catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000; 60: 4709-13
242. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basin of breast cancer: Oncogene 2000; 19: 1002-9.
243. Dale TC, Weber-Hall SJ, Smith K, et al. Compartment switching of WNT-2 expression in human breast tumors. Cancer Res 1996; 56: 4320-3.
244. Verras M, Brown J, Li X, Nurse R, Sun Z. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 2004; 64: 8860-6.
245. Hwang TS, Han HS, Hong YC, Lee HJ, Paik NS. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol Int 2003; 53: 74-80.
246. Shigemasa K, Tanimoto H, Parham GP, Parmley TB, Oharna K, O'Brien TJ. Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Investig 1999; 6:102-8.
247. Burd CJ, Petre CE, Morey LM, et al. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci USA 2006; 103: 2190-5.
248. Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote β-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 2002; 277: 17933-43.
249. Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002; 21: 2679-94.
250. Cronauer MV, Schulz WA, Ackermann R, Burchardt M. Effects of WNT/ β-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol 2005; 26: 1033-40.
251. Masiello D, Chen SY, Xu Y, et al. Recruitment of β-catenin by wild type or mutant androgen receptors correlates with ligand stimulated growth of prostate cancer cells. Mol Endocrinol 2004; 18: 2388-401.
252. Rios-Doria J, Kuefer R, Ethier SP, Day ML. Cleavage of β-catenin by calpain in prostate and mammary tumor cells. Cancer Res 2004; 64: 7237-40.
253. Zhu H, Mazor M, Kawano Y, et al. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res 2004; 64: 7918-26.
254. Cullen DA, Killick R, Leigh PN, Gallo JM. The effect of polyglutamine expansion in the human androgen receptor on its ability to suppress β-catenin-Tcf/Lef dependent transcription. Neurosci Lett 2004; 354: 54-8.
255. Castagnetta L, Traina A, Campisi I, et al. Androgen receptor status in nontumoral and malignant human colorectal tissues. Ann N Y Acad Sci 2002; 963: 322-5.
256. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175-86.
257. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58: 2720-3.
258. Manin M, Baron S, Goossens K, et al. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 2002; 366: 729-36.
259. Ohigashi T, Mizuno R, Nakashima J, Marumo K, Murai M. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 2005; 62: 61-8.
260. Somwar R, Kim DY, Sweeney G, et al. GLUT4 translocation precedes the stimulation of glucose uptake by insulin in muscle cells: potential activation of GLUT4 via p38 mitogen-activated protein kinase. Biochem J 2001; 359: 639-49.
261. Shiina H, Breault JE, Basset WW, et al. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. Cancer Res 2005; 65: 2130-8.
262. Pravettoni A, Mornati O, Martini PG, et al. Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: Studies on the possible mechanism of action in DU145 cells. Mol Cell Endocrinol 2007; 263: 46-54.